Safety Differences Across Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

References

• Surveillance, Epidemiology, and End Results Program . Cancer stat facts: prostate cancer (2022). https://seer.cancer.gov/statfacts/html/prost.html
   Google Scholar
• Wang L , LuB, HeM, WangY, WangZ, DuL. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front. Public Health10, 811044 (2022).
   PubMed Web of Science ®Google Scholar
• Catalona WJ . Prostate cancer screening. Med. Clin. North Am.102(2), 199–214 (2018).
   PubMed Web of Science ®Google Scholar
• Siegel DA , O’NeilME, RichardsTB, DowlingNF, WeirHK. Prostate cancer incidence and survival, by stage and race/ethnicity – United States, 2001–2017. MMWR Morb. Mortal. Wkly Rep.69(41), 1473–1480 (2020).
   PubMed Web of Science ®Google Scholar
• Saad F , BögemannM, SuzukiK, ShoreN. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis.24(2), 323–334 (2021).
   PubMed Web of Science ®Google Scholar
• Artibani W , PorcaroAB, DeMarco V, CerrutoMA, SiracusanoS. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol. Int.100(3), 251–262 (2018).
   PubMed Web of Science ®Google Scholar
• Uchio EM , AslanM, WellsCK, CalderoneJ, ConcatoJ. Impact of biochemical recurrence in prostate cancer among US veterans. Arch. Intern. Med.170(15), 1390–1395 (2010).
   PubMedGoogle Scholar
• European Association of Urology . EAU–EANM–ESTRO–ESUR–SIOG guidelines on prostate cancer (2022). https://uroweb.org/guideline/prostate-cancer/
   Google Scholar
• Scher HI , SoloK, ValantJ, ToddMB, MehraM. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLOS ONE10(10), e0139440 (2015).
   PubMed Web of Science ®Google Scholar
• El-Amm J , Aragon-ChingJB. The current landscape of treatment in non-metastatic castration-resistant prostate cancer. Clin. Med. Insights Oncol.13, 1179554919833927 (2019).
   Web of Science ®Google Scholar
• Anantharaman A , SmallEJ. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Rev. Anticancer Ther.17(7), 625–633 (2017).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . FDA approves apalutamide for non-metastatic castration-resistant prostate cancer (2020). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apalutamide-non-metastatic-castration-resistant-prostate-cancer
   Google Scholar
• US Food and Drug Administration . FDA approves darolutamide for non-metastatic castration-resistant prostate cancer (2020). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer
   Google Scholar
• Smith MR , SaadF, ChowdhurySet al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med.378(15), 1408–1418 (2018).
   PubMed Web of Science ®Google Scholar
• Hussain M , FizaziK, SaadFet al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med.378(26), 2465–2474 (2018).
   PubMed Web of Science ®Google Scholar
• Fizazi K , ShoreN, TammelaTLet al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med.380(13), 1235–1246 (2019).
   PubMed Web of Science ®Google Scholar
• Smith MR , SaadF, ChowdhurySet al. Apalutamide and overall survival in prostate cancer. Eur. Urol.79(1), 150–158 (2021).
   PubMed Web of Science ®Google Scholar
• Sternberg CN , FizaziK, SaadFet al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med.382(23), 2197–2206 (2020).
   PubMed Web of Science ®Google Scholar
• Fizazi K , ShoreN, TammelaTLet al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N. Engl. J. Med.383(11), 1040–1049 (2020).
   PubMed Web of Science ®Google Scholar
• Lowrance W , BreauR, ChouRet al. Advanced prostate cancer: AUA/ASTRO/SUO guideline part I–II. J. Urol.205, 14–22 (2021).
   PubMed Web of Science ®Google Scholar
• Lee VE , MohamedAF, ChenSL, WaldeckRA. Review of stakeholder preferences for non-metastatic castration-resistant prostate cancer treatments. J. Cancer Sci. Clin. Ther.5(1), 154–160 (2021).
   Google Scholar
• Tomaszewski EL , MoiseP, KrupnickRNet al. Symptoms and impacts in non-metastatic castration-resistant prostate cancer: qualitative study findings. Patient10(5), 567–578 (2017).
   PubMedGoogle Scholar
• Shah A , ShahR, KebedeNet al. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. J. Med. Econ.23(4), 330–346 (2020).
   PubMed Web of Science ®Google Scholar
• Kamal KM , CovveyJR, DashputreAet al. A systematic review of the effect of cancer treatment on work productivity of patients and caregivers. J. Manag. Care Spec. Pharm.23(2), 136–162 (2017).
   PubMed Web of Science ®Google Scholar
• Smith MR , ShoreN, TammelaTLet al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur. J. Cancer154, 138–146 (2021).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . Highlights of prescribing information: ERLEADA (apalutamide) (2022). www.accessdata.fda.gov/drugsatfda_docs/label/2022/210951s007lbl.pdf
   Google Scholar
• US Food and Drug Administration . Highlights of prescribing information: XTANDI (enzalutamide) (2022). www.accessdata.fda.gov/drugsatfda_docs/label/2022/203415s018,213674s005lbl.pdf
   Google Scholar
• US Food and Drug Administration . Highlights of prescribing information: NUBEQA (darolutamide) (2022). www.accessdata.fda.gov/drugsatfda_docs/label/2021/212099s001lbl.pdf
   Google Scholar
• Roumiguié M , PaolettiX, NeuzilletYet al. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. Future Oncol.17(14), 1811–1823 (2021).
   PubMed Web of Science ®Google Scholar
• Halabi S , JiangS, TerasawaEet al. Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer. J. Urol.206(2), 298–307 (2021).
   PubMedGoogle Scholar
• Mulati Y , FanY, YuW, ZhangQ, HeZ. Novel androgen receptor inhibitors in non-metastatic, castration-resistant prostate cancer: a systematic review and network meta-analysis. Front. Oncol.11, 733202 (2021).
   PubMed Web of Science ®Google Scholar
• Abbasi A , MovahedpourA, AmiriA, NajafMS, Mostafavi-PourZ. Darolutamide as a second-generation androgen receptor inhibitor in the treatment of prostate cancer. Curr. Mol. Med.21(4), 332–346 (2021).
   PubMed Web of Science ®Google Scholar
• Zurth C , SandmanS, TrummelD, SeidelD, NubbemeyerR, GieschenH. Higher blood-brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography. J. Clin. Oncol.37(Suppl. 7), 156–156 (2019).
   Web of Science ®Google Scholar
• Di Nunno V , MollicaV, SantoniMet al. New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. Clin. Genitourin Cancer17(5), e871–e877 (2019).
   PubMed Web of Science ®Google Scholar
• Drago JZ , GonenM, ThanarajasingamGet al. Inferences about drug safety in phase III trials in oncology: examples from advanced prostate cancer. J. Natl Cancer Inst.113(5), 553–561 (2021).
   PubMedGoogle Scholar
• Hird AE , DvoraniE, SaskinRet al. Prevalence and natural history of non-metastatic castrate resistant prostate cancer: a population-based analysis. J. Clin. Oncol.40(Suppl. 6), 65 (2022).
   Web of Science ®Google Scholar
• Arnold P , Penaloza-RamosMC, AdedokunLet al. Clinical characteristics and outcomes for patients with non-metastatic castration-resistant prostate cancer. Sci. Rep.11(1), 22151 (2021).
   PubMed Web of Science ®Google Scholar
• Appukkuttan S , PatelB, WrightJ, JaffeDH, CyhaniukA, SimmonsSJ. PCN231 Physician-reported comorbidities and treatment management in patients with non-metastatic castration-resistant prostate cancer. Value Health23(Suppl. 1), S63 (2020).
   Google Scholar
• Li H , HodgsonE, WatsonL, ShuklaA, NelsonJJ. Comorbidities and concomitant medication use in men with prostate cancer or high levels of PSA compared to matched controls: a GPRD analysis. J. Cancer Epidemiol.2012, 291704 (2012).
   PubMedGoogle Scholar
• Benoist GE , Van OortIM, SmeenkSet al. Drug–drug interaction potential in men treated with enzalutamide: mind the gap. Br. J. Clin. Pharmacol.84(1), 122–129 (2018).
   PubMed Web of Science ®Google Scholar
• Winters-Stone KM , MoeE, GraffJNet al. Falls and frailty in prostate cancer survivors: current, past, and never users of androgen deprivation therapy. J. Am. Geriatr. Soc.65(7), 1414–1419 (2017).
   PubMed Web of Science ®Google Scholar
• Shahinian VB , KuoYF, FreemanJL, GoodwinJS. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med.352(2), 154–164 (2005).
   PubMed Web of Science ®Google Scholar
• Smith MR , LeeWC, BrandmanJ, WangQ, BottemanM, PashosCL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J. Clin. Oncol.23(31), 7897–7903 (2005).
   PubMed Web of Science ®Google Scholar
• Appukkuttan S , FuC, DuYet al. Prevalence of potential drug–drug interactions among nonmetastatic castration-resistant prostate cancer patients treated with apalutamide and enzalutamide. J. Clin. Oncol.39(Suppl. 15), e18690–e18690 (2021).
   Web of Science ®Google Scholar
• Wong W , YimYM, KimAet al. Assessment of costs associated with adverse events in patients with cancer. PLOS ONE13(4), e0196007 (2018).
   PubMed Web of Science ®Google Scholar
• Appukkuttan SYJ , PartridgeJ, KongS, ParkinJ, FreedlandSJ. C30 Healthcare resource use and costs of adverse events among treated non-metastatic castration-resistant prostate cancer (nmCRPC) patients. J. Manag. Care Spec. Pharm.27, 10-b (2021).
   Google Scholar
• Lee VE , MohamedAF, ChenSL, WaldeckAR. Review of stakeholder preferences for non-metastatic castration-resistant prostate cancer treatments. J. Cancer Sci. Clin. Ther.5, 154–160 (2021).
   Google Scholar
• Pilon D , BehlAS, EllisLA, RobitailleMN, LefebvreP, DawsonNA. Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. Am. Health Drug Benefits10(3), 143–153 (2017).
   PubMed Web of Science ®Google Scholar
• Hussain A , JiangS, VargheseDet al. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. BMC Cancer22(1), 304 (2022).
   PubMed Web of Science ®Google Scholar
• Shore N , JiangS, Garcia-HortonVet al. The hospitalization-related costs of adverse events for novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer: an indirect comparison. Adv. Ther.39(11), 5025–5042 (2022).
   PubMed Web of Science ®Google Scholar
• Morgans AK , RenzulliJ2nd, OlivierK, ShoreND. Risk of cognitive effects in comorbid patients with prostate cancer treated with androgen receptor inhibitors. Clin. Genitourin. Cancer19(5), 467.e461–467.e411 (2021).
   Web of Science ®Google Scholar
• Shore N , ZurthC, FrickeRet al. Evaluation of clinically relevant drug–drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target. Oncol.14(5), 527–539 (2019).
   PubMed Web of Science ®Google Scholar
• Rashid N , KohHA, BacaHCet al. Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. J. Manag. Care Spec. Pharm.21(10), 863–871 (2015).
   PubMed Web of Science ®Google Scholar
• Rochon PA , GurwitzJH. The prescribing cascade revisited. Lancet389(10081), 1778–1780 (2017).
   PubMed Web of Science ®Google Scholar
• Kalisch LM , CaugheyGE, RougheadEE, GilbertAL. The prescribing cascade. Aust. Prescr.34, 162–166 (2011).
   Web of Science ®Google Scholar
• Rochon PA , GurwitzJH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ315(7115), 1096–1099 (1997).
   PubMed Web of Science ®Google Scholar
• Blumenthal D . Labeling an adverse drug event ‘preventable’. Virtual Mentor13(9), 601–608 (2011).
   PubMedGoogle Scholar
• Giardina TD , RoyseKE, KhannaAet al. Health care provider factors associated with patient-reported adverse events and harm. Jt Comm. J. Qual. Patient Saf.46(5), 282–290 (2020).
   PubMed Web of Science ®Google Scholar
• Busch IM , MorettiF, PurgatoM, BarbuiC, WuAW, RimondiniM. Dealing with adverse events: a meta-analysis on second victims’ coping strategies. J. Patient Saf.16(2), e51–e60 (2020).
   PubMed Web of Science ®Google Scholar
• Applegate WB . Physician management of patients with adverse outcomes. Arch. Intern. Med.146(11), 2249–2252 (1986).
   PubMedGoogle Scholar
• Laudicella R , AlbanoD, AlongiPet al. 18F-Facbc in prostate cancer: a systematic review and meta-analysis. Cancers (Basel)11(9), 1348 (2019).
   PubMed Web of Science ®Google Scholar
• Filippi L , BagniO, CrisafulliCet al. Detection rate and clinical impact of PET/CT with 18F-FACBC in patients with biochemical recurrence of prostate cancer: a retrospective bicentric study. Biomedicines10(1), 177 (2022).
   PubMed Web of Science ®Google Scholar
• Rowe SP , MacuraKJ, MenaEet al. PSMA-Based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol. Imaging Biol.18(3), 411–419 (2016).
   PubMed Web of Science ®Google Scholar
• Wang Y , GalanteJR, HaroonAet al. The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. Nat. Rev. Urol.19(8), 475–493 (2022).
   PubMed Web of Science ®Google Scholar
• Cattrini C , CaffoO, DeGiorgi Uet al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers (Basel)14(7), 1792 (2022).
   PubMed Web of Science ®Google Scholar